Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen announces positive MS follow-up study

Biogen announces positive MS follow-up study

31st July 2009

Biogen has announced positive data from a follow-up study into its Avonex (interferon beta-1a) therapy for Multiple Sclerosis (MS).

The company explained that the open-label Controlled High-Risk Avonex MS Prevention Study in Ongoing Neurologic Surveillance (Champions) trial is a follow-up to the Controlled High Risk Subjects Avonex MS Prevention Study (Champs) study.

Based on the results of the Champs trial, Avonex was granted approval for use in patients who experienced their first clinical MS episode with MRI findings.

Meanwhile, the Champions study showed that patients who were treated immediately following their first episode had a significantly lower chance of experiencing a second in comparison to those who delayed their treatment.

“The Champions study adds to the long-term follow-up data available and supports the benefits of starting early and staying on treatment with Avonex,” said Thorsten Eickenhorst, vice-president of global medical affairs at Biogen.

Earlier this year, the firm announced that it has received Food and Drug Administration approval for its high titer process used in the production of its MS drug Tysabri (natalizumab).

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.